Sept. 17, 2020
The National Institutes of Health has awarded Xunlei Kang, an assistant professor at the University of Missouri School of Medicine, a $1.7 million grant to study whether a drug used to treat Type 2 diabetes can prevent acute myeloid leukemia (AML) from spreading throughout the body.
AML accounts for more than 40% of leukemia-related deaths in the U.S., and most people with the disease die within a few years of diagnosis. Despite the numbers, Kang said there has not been progress in treatment in 40 years because targeting the diseased cells is difficult.
Kang and his team will use a Type 2 diabetes drug to try and delay — or even reverse — AML by targeting only the diseased myeloid stem cells and restraining them inside the bone marrow, which would stop them from entering the bloodstream and invading lymph nodes and other organs.
Want a healthy independent lifestyle? There’s a class for that
MU Study shows 8-week training program helps promote healthy lifestyle for seniors.
Leading the way
MU researcher Salman Hyder has spent a career battling breast cancer and mentoring the next generation of researchers.
Fostering ‘political’ attitude adjustments
MU study proposes narrative writing exercise as way to reduce polarization in U.S. politics.
A stinky job
MU scientists confirm human feces can provide an early warning of COVID-19 outbreak.
Stay up-to-date on all things Mizzou when you subscribe to the Show Me Mizzou newsletter. Issues will arrive in your inbox every Tuesday, Wednesday and Thursday.